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KEY POINTS 
• Low count and high count monoclonal B lymphocytosis (MBL) have distinct 
immunogenetic signatures, with only the latter resembling CLL. 
• Rather than a true premalignant condition, low count MBL may merely reflect 
immune senescence or result from persistent antigen stimulation. 
 
ABSTRACT 
 
CLL-like monoclonal B lymphocytosis (MBL) shares common immunophenotype and 
cytogenetic abnormalities with CLL, from which it is discriminated by a cut-off value 
of 5x109/l circulating clonal B cells. However, the clonal size amongst MBL is 
extremely variable and allows discrimination of two distinct entities (High- and Low-
count MBL) based on a cut-off value of 0.5x109/l clonal B cells. High-count (HC) MBL 
is associated with lymphocytosis and progresses to CLL requiring treatment at a rate 
of 1.1%/year, whereas low-count (LC) MBL is found in the general population only 
through high-sensitivity techniques and carries limited -if any- risk of progression. We 
performed an immunogenetic profiling of 333 CLL-like MBL cases supplemented by 
detailed comparisons with CLL, focusing especially on CLL Rai stage-0 (CLL-0). LC 
and HC-MBL had similar somatic hypermutation status, yet different IGHV gene 
repertoires and frequencies of B-cell receptor (BcR) stereotypy. In particular, 
stereotyped BcRs were infrequent in LC-MBL and often not CLL-specific. In contrast, 
HC-MBL exhibited clear immunogenetic similarities to CLL-0, extending to the 
frequent presence of CLL-specific stereotypes. These findings indicate that LC-MBL 
may not represent a true preleukemic condition, thus differing from HC-MBL/CLL-0 
where the identification of factors endowing malignant potential is strongly warranted.  
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INTRODUCTION 
 
The existence of monoclonal B cell expansions in the peripheral blood (PB) of 
healthy individuals has long been known,1-3 but has recently been more clearly 
appreciated and dissected thanks to advanced flow cytometry techniques.4-7 This 
condition falls under the general term “monoclonal B cell lymphocytosis” (MBL), even 
though it may not always correspond to an increase in the absolute lymphocyte 
count. MBL is classified according to the immunophenotype of the clonal population. 
Thus, the majority of MBL cases (75%) have the immunophenotype of chronic 
lymphocytic leukemia (CD5+, CD23+, CD20dim, sIgdim) and are defined as CLL-like 
MBL, whereas the remaining MBL cases are classified as atypical CLL-like (CD5+, 
CD20bright) and CD5-negative (CD5-) MBL.8,9 
CLL-like MBL is reported to be a premalignant state of CLL, analogous to the 
relationship between monoclonal gammopathy of undetermined significance and 
multiple myeloma.10 Its frequency ranges between 3 and 12%, depending on the 
sensitivity of the techniques utilized, and reaches 17% among CLL family 
members.5,6,11 
The World Health Organization (WHO) has set a consensus cut-off value of 5x109/l 
clonal B cells in the PB to discriminate what constitutes “disease” and what not.12 
That notwithstanding, below this limit the size of the clone both in absolute numbers 
as well as in percentage of circulating B cells is very heterogeneous, and MBL is now 
usually subdivided into two categories: “High-count” MBL (HC-MBL, also known as 
clinical MBL) and “Low-count” MBL (LC-MBL, also called population-screening 
MBL).8,13 The former is usually associated with lymphocytosis and is recognized in a 
clinical setting, thus explaining the initial name.14 The HC-MBL cases may progress 
to CLL requiring treatment at a rate of 1-2% per year.14 On the other hand, LC-MBL 
can only be detected by applying highly sensitive cytometric techniques in otherwise 
healthy individuals13, and has been described to remain stable over time, with no 
case progressing into HC-MBL or CLL within a 34-month follow-up time.15  
The jury is still out as to what, if any, is the best cut-off value for discriminating MBL 
into sub-entities with truly distinct biological and clinical significance. In clinical MBL, 
the clonal size in the PB has a median value of about 2.9x109 B cells/l and 95% of 
cases have more than 0.45x109 clonal B cells/l,16 whereas in LC-MBL the median 
number of clonal B cells is only 0.001x109/l.13 For all these reasons, a cut-off value of 
0.5x109 clonal B cells/l has been proposed for discriminating LC versus HC-MBL, 
based on the actual risk of progression.8,13  
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Thus, overall, the term MBL comprises a mixture of entities with different likelihood of 
representing a true preleukemic condition, as also indicated by the clinical data.4,15 
With this in mind, in the present paper we further pursue the possibility to understand 
the relationship between the different MBL cases and CLL by analyzing the 
immunoglobulin gene repertoire within a cohort of 333 individuals with CLL-like MBL, 
both LC (n=60) and HC (n=273), from collaborating institutions in Europe and the 
U.S. Comparisons of LC-MBL and HC-MBL to a large cohort of CLL cases and to a 
subgroup of Rai stage 0 CLL cases (CLL-0) revealed that LC and HC-MBL have 
different immunogenetic profiles and in particular that HC-MBL resembles CLL-0, 
whereas LC-MBL is clearly distinct from CLL. On these grounds, we believe that a 
reappraisal of MBL and its relationship to CLL is strongly warranted and clinically 
relevant. 
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PATIENTS AND METHODS 
 
Patient group 
A total of 333 patients diagnosed with CLL-like MBL from collaborating institutions in 
Europe and the US were included in the present study. All cases met the formal 
criteria for the diagnosis of MBL established in 2005.9 In particular, CLL-like MBL was 
defined on the basis of an unbalanced κ/λ ratio (>3:1 or <1:3) within CD19+, CD5bright, 
CD23+, CD20dim cells determined by flow cytometry. Within this cohort, 60 cases had 
a clonal B cell count of less than 0.5 x109/l (“low count”, LC-MBL), whereas the 
remaining 273 cases had from 1.5 to less than 5.0 x109/l clonal B cells with a CLL-
like phenotype (“high count”, HC-MBL) (Table 1). There was no case of LC-MBL with 
increased T cells or polyclonal B cells that would result in absolute lymphocytosis. 
The distribution of MBL cases according to clonal size is depicted in Figure 1. The 
study was approved by the local Ethics Review Committee of each institution. The 
study was conducted in accordance with the Declaration of Helsinki. 
 
PCR amplification of IGHV-IGHD-IGHJ rearrangements 
PCR amplification of IGHV-IGHD-IGHJ rearrangements were performed on either 
genomic DNA (gDNA) or complementary DNA (cDNA), as previously described.4,17  
 
Sequence analysis and interpretation 
PCR amplicons were subjected to either direct sequencing on both strands or, in 15 
cases, after subcloning; in the latter case, at least 10 colonies were analyzed per 
amplicon.  
Sequence data were analyzed using the IMGT® databases18 and the IMGT/V-
QUEST tool (http://www.imgt.org).19 Codons and amino acid positions are according 
to the IMGT unique numbering for V domain.20 Only productive rearrangements were 
evaluated (n=355). 
Rearrangements utilizing the IGHV4-59 and IGHV4-61 genes were considered as 
one group because the usage of an FR2-primer for certain PCR amplification 
experiments precluded a clear assignment to either one or the other IGHV gene that 
differ mainly in the VH FR1-VH CDR1. In order to avoid misidentification of mutations 
when IGHV FR1 or FR2 consensus primers were used in the amplification reactions, 
nucleotide substitutions in the obtained sequences were evaluated from codon 27 in 
CDR1-IMGT or from codon 56 in CDR2-IMGT in those sequences obtained with a 
VH FR2 primer.4 
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IG repertoire comparisons and VH CDR3 clustering 
IG gene repertoire comparisons were performed for the IGHV-IGHD-IGHJ 
sequences from MBL cases included in the present study and 7596 IGHV-IGHD-
IGHJ sequences from a cohort of 7424 CLL cases from our recent publication.21 
Comparisons were also performed between MBL and a subgroup of the CLL cohort 
including only Rai stage 0 cases from three collaborating institutions within our 
network (San Raffaele, Milan; G. Papanicolaou, Thessaloniki; Nikea General 
Hospital, Athens) attending patients with CLL found in everyday clinical practice, i.e. 
without any selection bias (“community CLL”) (n=544 cases). 
Furthermore, MBL sequences from our series were aligned and compared to a panel 
of 5494 non-redundant, well annotated and productive IGHV-IGHD-IGHJ sequences 
from various entities except CLL which were retrieved from the IMGT/LIGM-DB 
sequence database (http://www.imgt.org/IMGTindex/LIGM.html); this panel has also 
been used for the same purpose in previous repertoire studies from our group.4,22,23  
In order to assess BcR IG stereotypy within the entire collection of IGHV-IGHD-IGHJ 
sequences (MBL, CLL, other entities) we followed a clustering process based on 
purpose-built bioinformatics as previously described.22 
 
Statistical analysis 
Descriptive statistics for discrete parameters included counts and frequency 
distributions. For quantitative variables, statistical measures included means, 
medians, and min–max values. Significance of bivariate/multivariate relationships 
between variables was assessed with the use of chi-square. For all comparisons, a 
significance level of p=0.05 was set and all statistical analyses were performed with 
the statistical package GraphPad Prism version 5.0 (GraphPad Software, Inc., San 
Diego, USA). 
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RESULTS 
 
Low-count and high-count MBL have distinct IG gene repertoires 
Overall, 355 productive IGHV-IGHD-IGHJ rearrangements were amplified from 333 
cases with CLL-like MBL. When we differentiated MBL based on the absolute clonal 
B cell count - LC-MBL, <0.5x109/l (median 0.008x109/l); HC-MBL, ≥0.5x109, 
<5.0x109/l (median 3.38x109/l) (Table 1) - we noted that a significantly higher 
proportion of LC-MBL versus HC-MBL carried multiple productive IGHV-IGHD-IGHJ 
rearrangements (7/60 (11.7%) versus 8/273 (2.9%) cases, p=0.003). Among all 
studied rearrangements, IGHV3 was the predominant subgroup (175/355, 49.3%), 
followed by IGHV4 (87/355, 24.5%). Thirty-nine functional IGHV genes were 
identified. The most frequent gene was IGHV4-34 (42 rearrangements, 11.8%) 
followed by IGHV3-23 (8.7%), IGHV3-7 (8.5%), IGHV1-69 (6.8%) and IGHV4-59/61 
(6.8%) (Supplemental Table 1).  
Significant differences were identified regarding the frequencies of IGHV genes 
between LC-MBL versus HC-MBL. At subgroup level, IGHV4 genes were 
significantly (p=0.02) under-represented and IGHV1 genes were significantly over-
represented (p=0.04) in HC-MBL vs. LC-MBL. At the individual gene level, the 
IGHV1-69, IGHV2-5, IGHV3-23, IGHV3-33, IGHV3-48 and IGHV4-34 genes 
predominated in HC-MBL vs. LC-MBL, however the observed differences did not 
reach statistical significance likely due to small sample size (at least for statistical 
purposes). With this in mind (i.e. relatively low numbers), it is indeed remarkable that 
the IGHV4-59/61 gene was highly significantly (p<0.0001) more frequent in LC-MBL 
versus HC-MBL (Figure 2, Supplemental Table 1).  
Regarding VH CDR3 length and composition as well as IGHD and IGHJ gene usage, 
detailed results are provided in Supplemental Tables 2-4.  
Following the 98% germline identity (GI) cut-off value, 267/355 (75.2%) 
rearrangements were assigned to the mutated subgroup, whereas the remaining 
(88/355, 24.8%) were classified as unmutated, of which 52/88 (59.1%) had 100% 
sequence identity to the corresponding germline IGHV gene. No differences were 
identified in terms of somatic mutations in LC vs. HC-MBL as evidenced by an overall 
similar distribution of cases to the mutated vs. unmutated subgroups. Interestingly, 
however, in MBL cases with multiple productive IGHV-IGHD-IGHJ rearrangements, 
the mutational status was generally concordant in LC-MBL (5/7 cases, 71.5%, with 
only mutated IGHV genes) whereas it was often discordant in HC-MBL (5/8 cases, 
62.5%, with co-existing mutated and unmutated IGHV genes). 
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Low-count MBL have a distinct IG gene repertoire whereas high-count MBL 
resemble Rai stage 0 CLL 
We next compared the IG gene repertoire between MBL and CLL. To this end, we 
used as reference two CLL datasets, one exclusively comprising 544 CLL-0 cases 
and the other one 7424 cases in all clinical stages (thereafter designated as CLL-all 
stages, as detailed in the Patients and Methods section). In keeping with our 
previous report,4 the most pronounced difference concerned the IGHV4-59/61 gene, 
which was significantly over-represented in LC-MBL (p<0.0001) (Figure 2). A 
significantly different distribution was also noted for the IGHV1-69 gene, which was 
rare in LC-MBL (2.8%), utilized with similar, higher frequencies in HC-MBL and CLL-
0 (7.8% and 5.5%, respectively) and peaked at 12.8% in CLL-all stages, being the 
most frequent gene overall (p<0.0001). Other examples of IGHV genes with 
asymmetric usage in the compared groups are given in Supplemental Table 5.  
Regarding the mutational status of the IG rearrangements, no differences were 
identified between LC-MBL versus HC-MBL versus CLL-0, as the frequency of 
unmutated rearrangements (≥98% GI) was overall similar (LC-MBL: 26.4%, HC-MBL: 
24.4%, CLL-0: 25%). Hence, all the aforementioned subgroups differed significantly 
(p=0.001, p<0.0001, and p<0.0001, respectively) from CLL-all stages where almost 1 
out of 2 (45.1%) rearrangements carried unmutated IGHV genes (Figure 3). 
Interestingly, in both HC-MBL and CLL-0, a sizeable proportion, roughly one-third of 
rearrangements utilizing the IGHV1-69 gene were mutated (7/22, 31.8% and 9/30, 
30%, respectively), thus differing significantly (p<0.001) from CLL-all stages, where 
less than 10% of all such rearrangements were mutated. In the LC-MBL group, only 
2 cases utilized the IGHV1-69 gene, and it was mutated in both.  
 
BcR stereotypy is infrequent in low-count MBL, with the occasional 
stereotyped BcRs constituting “public” immunogenetic signatures 
Analysis of the VH CDR3 region was possible in 349/355 rearrangements of the MBL 
cohort. In order to identify stereotyped VH CDR3s, we applied our purpose-built 
algorithm for the identification of shared VH CDR3 amino acid patterns and 
performed cluster analysis of the MBL sequences.22 Next, we also compared the 
MBL VH CDR3 dataset against 7596 CLL sequences from our recent publication.21 
Finally, we also performed sequence comparisons with 5494 non-redundant, well-
annotated and complete VH CDR3 sequences from various entities except CLL 
which were retrieved from the IMGT/LIGM-DB sequence database.  
When we compared the frequency of “CLL-specific” BcR stereotypes between LC-
MBL and HC-MBL, this was significantly higher in HC-MBL (p=0.001), further 
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underscoring a difference in the immunogenetic profile between these two entities. 
Specifically, only 4/72 (5.5%) LC-MBL IG sequences, none from cases with multiple 
productive IGHV-IGHD-IGHJ gene rearrangements, could be clustered with other 
sequences in subsets with stereotyped BcRs; they concerned cases with clonal B 
cells in the range of 0.004-0.055 x109/l. In particular, (i) 1 LC-MBL case was 
clustered together with a HC-MBL case, but with no CLL cases, thus forming a novel 
“MBL-specific” subset; (ii) 1 LC-MBL case could be assigned to a “CLL-specific” 
subset (subset #239); (iii) 2 LC-MBL cases were clustered together with sequences 
from various entities, including CLL, thus they were considered to carry “public” BcR 
stereotypes (see following section). 
In contrast, 62/283 (21.9%) HC-MBL rearrangements carried VH CDR3s similar to 
either other MBL or CLL cases; 3/62 were detected in cases with multiple 
rearrangements. In particular, (i) 45 HC-MBL cases clearly belonged to well-
established “CLL-specific” subsets (e.g. #1, #2, #4, #16, #28 etc); (ii) 10 HC-MBL 
cases clustered together with CLL, forming novel “MBL-CLL” subsets; (iii) 5 HC-MBL 
cases clustered together, forming “MBL-specific” subsets; and, (iv) 2 HC-MBL cases 
carried “public” IG BcR stereotypes, i.e. were assigned to clusters including 
sequences from various entities (see following section).  
Furthermore, a progressive increase in the frequency of BcR IG stereotypy 
depending on the absolute count of CLL-like cells could be observed, starting with 
5.5% in LC-MBL, rising to 21.9%/20.2% in HC-MBL/CLL-0, respectively, and peaking 
at 30.4% in CLL-all stages (Figure 4).  
 
Public BcR IG stereotypes in the MBL repertoire 
The first LC-MBL case with a “public” BcR IG stereotype (89VBB) was assigned to a 
subset of sequences from mainly CLL (subset #13) though also including other 
sequences as well (a rheumatoid factor from a healthy individual, the clonotypic BcR 
of a case with splenic marginal-zone lymphoma, two cases with Sjögren's syndrome-
associated myoepithelial sialadenitis (SS-MESA) and a CLL case with prior HCV-
associated type-II mixed cryoglobulinemia (HCV/MC-II). As we recently reported,24 a 
number of cases assigned to this subset, regardless of the underlying diagnosis, had 
positive HCV serology; this was the case for 89VBB as well.  
The second LC-MBL case with a “public” BcR IG stereotype (87VB) carried a VH 
CDR3 similar to the one recently reported in our study of ocular adnexa marginal-
zone lymphoma (OAMZL) (Figure 5A).25 This particular stereotype has so far been 
detected among various entities in addition to OAMZL, including CLL (2 cases), 
salivary-gland MALT lymphoma (1 case), gastric MALT lymphoma (1 case), diffuse 
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large B cell lymphoma (1 case, positive for HCV) and, finally, a rheumatoid factor. All 
these cases shared quasi-identical VH CDR3s and, furthermore, also exhibited a 
“stereotyped” somatic hypermutation in VH CDR2 codon 58, leading to substitution of 
proline for glutamine (Figure 5B).  
Only 2 HC-MBL rearrangements were clustered together with sequences from 
different entities except CLL that were retrieved from the IMGT/LIGM-DB sequence 
database. The first carried a mutated BcR IG, which was quasi-identical with a 
rheumatoid factor. The second clustered with the BcR IG from a salivary MALT 
lymphoma and the autoreactive BcR IG from a patient with primary Sjögren's 
syndrome.   
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DISCUSSION 
 
CLL-like MBL is generally considered to represent tout court a pre-CLL state, in 
analogy to what Monoclonal Gammopathy of Undetermined Significance (MGUS) is 
for multiple myeloma.26 Along this line, a prospective cohort study demonstrated that 
CLL is always preceded by CLL-like MBL.10 However, the frequency of CLL-like MBL 
is particularly high among the general population, reaching 12% when advanced flow 
cytometric techniques are used,5 thereby being at least 100 times more frequent than 
CLL and highlighting the fact that not all MBL carry the same risk of clinical 
progression.15 It is therefore of crucial relevance to clearly distinguish those cases 
that are more likely to progress and require special clinical attention during follow-up. 
Studying the biological characteristics of MBL may then help us identify prognostic 
markers that correlate with progression toward CLL, sparing the majority of cases 
from unnecessary psychological distress and continuous medical attention with the 
obvious social and economic implications. 
So far, the absolute clonal B lymphocyte count is the only factor that was found to 
hold some prognostic value for the progression of MBL into CLL requiring 
treatment.13 Based on survival curves, it has been proposed that MBL may be 
subdivided into two groups, Low Count and High Count, by being below or above a 
suggested cut-off of 0.5x109 clonal cells/l, respectively.14,16 Recently, our group 
demonstrated that LC-MBL carries distinct biological features, including the IG gene 
repertoire, from CLL, both mutated and unmutated, and supported the idea that this 
entity may not always be equivalent to a premalignant state.4  
Here, we analyzed a large, multinational cohort of CLL-like MBL cases, both LC and 
HC, which allowed us to perform informative IG gene repertoire comparisons of LC-
MBL, HC-MBL, CLL-0 and CLL-all stages. For all comparisons, we followed the cut-
off of 0.5x109 clonal cells/l to discriminate LC from HC-MBL. This cut-off was not only 
suggested by the literature but also an educated choice; use of other cut-off values, 
(namely 1.0 and 1.5x109/l) did not affect our conclusions since our MBL cohort was 
polarized towards carrying either really low-count clones or >1.5x109 clonal B cells/l, 
and cases with a clonal B cell count between 0.5 and 1.5x109/l were in essence very 
few (n=17) (Figure 1).  
The analysis of the IGHV genes expressed by LC-MBL revealed significant 
differences from HC-MBL as well as from CLL-all stages in terms of both gene usage 
and, perhaps more importantly, the frequency of BcR stereotypy. Interestingly, HC-
MBL showed great similarity with CLL, especially CLL stage Rai 0. In contrast, 
compared to both HC-MBL and CLL, LC-MBL exhibits pronounced differences e.g. 
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suppressed frequency of the IGHV1-69 gene and overrepresentation of the IGHV4-
59/61 genes, confirming our previous findings.4 The underrepresentation of the 
IGHV1-69 gene in LC-MBL may be associated with the overall paucity of stereotyped 
BcRs in this category, as this gene shows a remarkable propensity to be utilized in 
stereotyped rearrangements in CLL.22,23  
The latter have been shown to be a distinctive feature of CLL being present in almost 
one-third of cases.21,22 Hence, our present finding that stereotyped receptors are 
indeed rare in LC-MBL is particularly noteworthy, again suggesting a phylogenetic 
distance from CLL, whereas HC-MBL is characterized by a much higher frequency of 
BcR stereotypes, surprisingly similar to that of CLL stage 0, to which again seems to 
be more closely related at the biological level.  
One also has to consider that HC-MBL cases have been demonstrated to carry a risk 
of evolution into CLL needing treatment at a sizeable frequency between 1-
4%/year,14,16,27 while CLL stage 0 patients will require therapy at an approximate rate 
of 5%/year.28 This indicates that both entities comprise a mixture of cases with 
distinct overall propensity of progression and suggests the need to identify molecular 
or clinical signatures, besides the official threshold of 5x109 clonal B cells/l, to 
distinguish between progressive and non-progressive cases regardless the actual 
MBL or CLL diagnosis.  
From a clinical standpoint, our immunogenetic data further supports the idea that 
HC-MBL should be managed as CLL not requiring treatment, i.e. with regular follow-
ups. It remains to be established in prospective studies whether it may be worth 
evaluating the IGHV gene usage, mutational status and/or BcR stereotypy in an 
effort to obtain information that could be of use in identifying the small fraction of 
cases that will eventually progress. In this respect, it is worth mentioning that the 
most common subset recognized among this HC-MBL cohort was subset #2 
(expressing IGHV3-21/IGHJ6 VH CDR3; 10%, 7/72 stereotyped HC-MBL clones). 
Subset #2 is conspicuous for its aggressive clinical behavior,29-31 so it would not be 
unreasonable to speculate that a HC-MBL case also expressing this stereotype 
should be followed more closely, though this remains to be proven.  
On the other hand, the overrepresentation of the IGHV4-59/61 genes in LC-MBL 
closely parallels the significant increase of this gene among elderly individuals,32 
suggesting that it might simply mirror the age-related repertoire restriction occurring 
in healthy individuals with age.33-35 This further supports the possibility that LC-MBL 
may simply represent an aspect of the physiological process of immune-senescence. 
Similar repertoire restrictions are well established for the T cell peripheral pool, 
where the TCR diversity appears to collapse with age, especially in the CD8+ but also 
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in the CD4highCD8low compartment.36-38 The frequent presence in the elderly of clonal 
expansions among the CD8+ T cells, but even more interestingly among normally 
negligible peripheral T-cell subsets, closely resembles CLL-like MBL in healthy 
individuals, the frequency of which is also age-related.5,39,40 The finding of "public 
signatures" among BcR stereotypes in LC-MBL further supports the notion that LC-
MBL does not necessarily represent a preleukemic condition rather it may reflect 
repertoire restriction/polarization due to immune senescence and/or chronic antigenic 
stimulation.41 Along the same line lies the conspicuously increased frequency of 
multiple productive rearrangements in LC-MBL. Expression of multiple antigen 
receptors has been reported for autoreactive B cells, where constant exposure to 
self-antigens may ultimately lead to allelic "inclusion" as an editing mechanism 
(otherwise described as “receptor dilution”).42-44 In sharp contrast, the frequency of 
multiple productive rearrangements in HC-MBL was similar to the one reported for 
CLL.45 Altogether, these findings support the notion that LC-MBL might constitute 
another example where clonality does not directly translate to malignancy and cast 
serious doubts on its relation with CLL.  
Against this contention, the seemingly indolent nature of LC-MBL has to be 
reconciled with the finding of the same cytogenetic abnormalities that are frequently 
encountered in CLL (del13q, trisomy 12, del17p).15 However, as we recently 
reported, all LC-MBL cases, even those cases carrying cytogenetically abnormal 
clones, showed no evidence of progression from the low-count state during a median 
follow-up time of 34 months.15 This may well stand in analogy to the detection of 
“lymphoma-associated” translocations in circulating B cells of healthy individuals, e.g. 
the follicular lymphoma-associated t(14;18) (with reported frequencies ranging from 
30% to >70%)46-49 and the mantle cell lymphoma-associated t(11;14) (which is rarer, 
1-7%).50,51 Altogether, it is reasonable to argue that genetic aberrations may occur 
early in the timeline of MBL, perhaps as a result of persistent proliferative stimuli by 
antigen(s), and relate more to the acquisition of the aberrant (or persistently 
activated?) phenotype rather than the malignant state itself. 
One could argue that, since HC-MBL/CLL probably stems from a single cell that 
clonally expands as it gradually suffers malignant hits, it must "transit" through the 
LC-MBL range as well. We believe that in LC-MBL the clonal population that results 
from persistent antigenic stimulation is contained despite the fact that the proliferative 
stimuli lead to the acquisition of genetic aberrations. Perhaps HC-MBL/CLL may 
develop only when this microenvironmental drive occurs in a background of genetic 
predisposition, with the expanded clone having inherently different tendencies to 
quickly transit from the LC-MBL to the HC-MBL/CLL phase. This theory appears to 
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be also supported by the polarized distribution of the MBL cases in our cohort, where 
few MBL cases carry a clone size of 0.5-1.5 x109 cells/l, instead they carry either 
really low-count clones (median clonal B cell count of 0.008 x109/l), or clones >1.5 
x109 cells/l. 
Due to such small clonal size, LC-MBL hardly causes by itself any perturbation in the 
blood count differential and requires application of high-sensitivity flow cytometry 
protocols in order to be identified. Therefore, a physician will not likely encounter this 
entity in everyday practice. In any case, our immunogenetic data suggest that this 
condition is not clinically relevant and should not prompt monitoring neither analysis 
of biological prognostic markers, unless for research purposes.  
In conclusion, while LC-MBL likely results from persistent antigenic stimulation, the 
relevant immune pathways can be distinct from those implicated in the ontogeny of 
CLL, especially the stereotyped category. On the contrary, HC-MBL has remarkable 
immunogenetic similarities to CLL-0, extending from similar IGHV gene usage to 
similar frequency of “CLL-specific” BcR stereotypes, which reinforce their 
immunobiological relatedness, besides their clinical proximity. Therefore, thorough 
molecular analysis and characterization of BcR stereotypy combined with long-term 
clinical monitoring of HC-MBL may help in clarifying the degree to which “CLL-
biased” stereotypy can serve as a predictor for evolution to CLL. 
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TABLES 
 
 
LC-MBL
 
HC-MBL
 
MBL cell range (x10
9
/l)
 
0-0.5
 
0.5-5.0
 
Number of cases
 
60
 
273
 
Number of productive rearrangements 72 283 
Median B cell count (x10
9
/l) 
 
0.14
 
3.52
 
Median MBL cell count (x10
9
/l)
 
0.008
 
3.38
 
MBL/B cell percentage (average)
 
21%
 
93%
 
Median absolute lymphocyte count (x10
9
/l) 2.17 6.0 
 
Table 1. Characteristics of the MBL cohort regarding absolute and relative clonal 
size. 
 only.
For personal use at BIBLIOTECA POLO SAN PAOLO on April 22, 2013. bloodjournal.hematologylibrary.orgFrom 
23 
 
 
FIGURES  
 
 
 
Figure 1. A) Distribution of all MBL cases according to clonal size. Each case is 
represented with a dot. The cohort is polarized towards carrying either really small 
clones or >1.5x109 MBL cells/L. B) Distribution of LC-MBL cases according to clonal 
size. For reasons of better visualization, the x axis is split in two differently scaled 
segments (<0.005 and ≥0.005 MBL cells/L). Most LC-MBL cases carry clones 
consisting of <0.1x109 MBL cells/L. 
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Figure 2. IGHV gene repertoire comparison in low count MBL versus high count 
MBL versus CLL-0 versus CLL-all stages. 
Differences at level of statistical significance p<0.05 and p<0.001 are marked with [*] and [***], 
respectively.   
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Figure 3. The frequency (%) of unmutated IG rearrangements (≥98% germline 
identity) in MBL and CLL.  
Differences at level of statistical significance p<0.01 and p<0.001 are marked with [**] and [***], 
respectively. 
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Figure 4.  The frequency (%) of BcR IG stereotypy in MBL and CLL.  
Differences at level of statistical significance p<0.01 and p<0.001 are marked with [**] and [***], 
respectively. 
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Figure 5. A) VH CDR3 similarity between the LC-MBL case 87VB and unrelated 
sequences. Dashes indicate identities. B) Somatic hypermutation in the VH region 
of the LC-MBL case 87VB and co-clustered sequences, as visualized using 
TeXshade peptide alignment tool (http://workbench.sdsc.edu/). The VH region is 
shown from IMGT positions 21 to 104. The letters above the line represent the 
amino acid changes, whereas the letters shown upside-down below the line 
represent the corresponding germ line amino acids of the IGHV gene. The size of 
the amino acid symbol represents the relative frequency of that amino acid at that 
position relative to all other mutations at that position in the certain IGHV group of 
sequences. Blank spaces represent amino acids that are unchanged in comparison 
to the germ line sequence.  
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